Keyword Connections

•  Albert Reynolds
•  Alexander Zaika

•  H. Ruley
•  Scott Hiebert

•  Stephen Hann

Resources

• No matching connections

Communities

• Hiebert Lab

Publications

• p19ARF directly and differentially controls the functions of c-Myc independently of p53.
  Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR
  (2004) Nature 431: 712-7
• Telomere dysfunction induces metabolic and mitochondrial compromise.
  Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA
  (2011) Nature 470: 359-65
• Comprehensive genomic profiles of small cell lung cancer.
  George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK
  (2015) Nature 524: 47-53
• Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
  Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW
  (2005) Nature 436: 807-11
• Somatic mutations affect key pathways in lung adenocarcinoma.
  Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK
  (2008) Nature 455: 1069-75
• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
  Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sänger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK
  (2012) Nat Genet 44: 1104-10
• M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity.
  De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL
  (1995) Nat Genet 11: 447-9
• Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity.
  Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, Sleeman MW, Oliver G
  (2005) Nat Genet 37: 1072-81
• Germline BAP1 mutations predispose to malignant mesothelioma.
  Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M
  (2011) Nat Genet 43: 1022-5
• Bid plays a role in the DNA damage response.
  Zinkel SS, Hurov KE, Gross A
  (2007) Cell 130: 9-10; author reply 10-1
• A role for proapoptotic BID in the DNA-damage response.
  Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A, Korsmeyer SJ
  (2005) Cell 122: 579-91
• HIF-1alpha is essential for myeloid cell-mediated inflammation.
  Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS
  (2003) Cell 112: 645-57
• Under pressure: stromal fibroblasts change their ways.
  Bierie B, Moses HL
  (2005) Cell 123: 985-7
• The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor.
  Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, Shyr Y, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ
  (2012) Cell 149: 146-58
• Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.
  Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Wulf GM, Bell EL, Shim HS, Lamia KA, Rameh LE, Bellinger G, Sasaki AT, Asara JM, Yuan X, Bullock A, Denicola GM, Song J, Brown V, Signoretti S, Cantley LC
  (2013) Cell 155: 844-57
• Epidermal sensing of oxygen is essential for systemic hypoxic response.
  Boutin AT, Weidemann A, Fu Z, Mesropian L, Gradin K, Jamora C, Wiesener M, Eckardt KU, Koch CJ, Ellies LG, Haddad G, Haase VH, Simon MC, Poellinger L, Powell FL, Johnson RS
  (2008) Cell 133: 223-34
• A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.
  Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K
  (1993) Cell 72: 791-800
• CRISPR-Cas9 knockin mice for genome editing and cancer modeling.
  Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F
  (2014) Cell 159: 440-55
• Trefoil peptides: less clandestine in the intestine.
  Chinery R, Coffey RJ
  (1996) Science 274: 204
• Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
  Cortez D, Wang Y, Qin J, Elledge SJ
  (1999) Science 286: 1162-6
• Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein.
  Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, Wendling C, Tomasetto C, Chambon P, Rio MC
  (1996) Science 274: 259-62
• A 'Tsc, Tsc' keeps the kids quie(scen)t and holds down ROS.
  Boothby M, Lee K
  (2011) Nat Immunol 12: 811-2
• Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.
  Zhang B, Beeghly-Fadiel A, Long J, Zheng W
  (2011) Lancet Oncol 12: 477-88
• Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
  Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J
  (2013) Lancet Oncol 14: 159-167
• Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.
  Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Rozenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M
  (2013) Cancer Cell 23: 634-46
• Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.
  Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, Schlisio S
  (2005) Cancer Cell 8: 155-67
• p53 and MDM2: antagonists or partners in crime?
  Eischen CM, Lozano G
  (2009) Cancer Cell 15: 161-2
• Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene.
  Stairs DB, Bayne LJ, Rhoades B, Vega ME, Waldron TJ, Kalabis J, Klein-Szanto A, Lee JS, Katz JP, Diehl JA, Reynolds AB, Vonderheide RH, Rustgi AK
  (2011) Cancer Cell 19: 470-83
• Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth.
  Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC
  (2003) Cancer Cell 3: 75-88
• Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors.
  Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, Lechel A, Rudolph KL, Langer R, Slotta-Huspenina J, Bader FG, Prazeres da Costa O, Neurath MF, Meining A, Kirchner T, Greten FR
  (2013) Cancer Cell 23: 93-106
• A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.
  Rad R, Cadiñanos J, Rad L, Varela I, Strong A, Kriegl L, Constantino-Casas F, Eser S, Hieber M, Seidler B, Price S, Fraga MF, Calvanese V, Hoffman G, Ponstingl H, Schneider G, Yusa K, Grove C, Schmid RM, Wang W, Vassiliou G, Kirchner T, McDermott U, Liu P, Saur D, Bradley A
  (2013) Cancer Cell 24: 15-29
• LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB.
  Wang J, An H, Mayo MW, Baldwin AS, Yarbrough WG
  (2007) Cancer Cell 12: 239-51